ICAP
AC-14 - CENP-F-like
Previous Nomenclature MSA-3, NSp-II
Description Nuclear speckled pattern with striking variability in intensity with the strongest staining in G2 phase and weakest/negative staining in G1. The centromeres are positive only in prometaphase and metaphase, revealing multiple aligned small and faint dots. Prometaphase cells frequently show a weak staining of the nuclear envelope. During anaphase and telophase, some sera demonstrate intense staining in the ring located at the midzone (i.e. mid-body, stem body) where the division of the daughter cells is taking place. The surrounding cytoplasm of the mitotic cells is diffusely stained.
Antigen Association CENP-F
Clinical Relevance
First level information
About Clinical Relevance

The majority of sera exhibiting the AC-14 pattern are from patients with a diversity of neoplastic conditions (breast, lung, colon, lymphoma, ovary, brain); paradoxically, the frequency of the AC-14 pattern in patient cohorts with these malignancies is low

The AC-14 pattern is also seen in inflammatory conditions (Crohn’s disease, autoimmune liver disease, SjS, graft-versus-host disease); current information on clinical associations is based mainly on case reports and series of cases

Possible associations only hold if the reactivity to CENP-F is confirmed in an antigen-specific immunoassay; current information on clinical associations is based mainly on case reports and series of cases; specific immunoassays for this autoantibody are currently not commercially available (74–78)

First level information references
74.
Casiano CA, Landberg G, Ochs RL, et al. Autoantibodies to a novel cell cycleregulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci 1993;106:1045–56.
75.
Casiano CA, Humbel RL, Peebles C, et al. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun 1995;8:575–86.
76.
Rattner JB, Rees J, Whitehead CM, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997;20:308–19.
77.
Bencimon C, Salles G, Moreira A, et al. Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Ann N Y Acad Sci 2005;1050:319–26.
78.
Welner S, Trier NH, Frisch M, et al. Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay. Mol Cancer 2013;12.
Second level information
None
Second level information references
None
FAQ
No FAQ received
 
 
Online since 19 May 2015